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Purpose: Type 2 idiopathic macular telangiectasia (MacTel) is a rare bilateral neurode-
generative disease characterized by alterations in the macular capillary network leading to
central vision loss. The purpose of this study was to quantify disease-speciﬁc retinal
ﬂuorescence lifetime patterns in patients with MacTel using ﬂuorescence lifetime imaging
ophthalmoscopy.
Participants: Both eyes of 14 patients (mean age ± SEM, 67.8 ± 6.4 years) with a clinical
diagnosis of MacTel Type 2 and 14 healthy age-matched controls (age 69.8 ± 6.4 years)
were included in this study.
Methods: All participants were imaged with a ﬂuorescence lifetime imaging ophthal-
moscope (Heidelberg Engineering, Germany). Mean retinal ﬂuorescence lifetimes (Ƭm) were
obtained in the short spectral channels (498–560 nm) and long spectral channels (560–720
nm). Clinical features, fundus images, fundus autoﬂuorescence intensity images, spectral
domain optical coherence tomography, and corresponding macular pigment optical den-
sity measurements using a modiﬁed confocal scanning laser ophthalmoscope (mpHRA)
were further analyzed. Patients were classiﬁed into ﬁve phenotypic subgroups using the
Gass and Blodi classiﬁcation.
Results: Mean ﬂuorescence lifetimes were signiﬁcantly prolonged temporal to the fovea
in patients with MacTel compared with healthy controls (mean ± SEM: short spectral
channels 543 ± 61 ps vs. 304 ± 9 ps; P , 0.0001; long spectral channels: 447 ± 26 ps
vs. 348 ± 11 ps; P , 0.0001), and appeared as a crescent or ring-shaped pattern. Pro-
longed lifetime patterns correlated with decreased macular pigment density on macular
pigment optical density measurements. Follow-up examinations were performed in four
MacTel patients, which revealed an increase of short spectral channel Ƭm of 22% over
2.1 years in the temporal fovea.
Conclusion: This study conﬁrms that fundus autoﬂuorescence lifetimes display
characteristic patterns in patients with MacTel Type 2 disease and provide information
about macular pigment and possibly photoreceptor loss. Fluorescence lifetime pro-
longation correlates with disease severity and may therefore be a useful addition to other
imaging modalities for assessing disease progression in MacTel Type 2.
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Idiopathic macular telangiectasia Type 2 (MacTel) isa rare bilateral neurodegenerative disease, character-
ized by alterations of the retinal capillary network in
the juxtafoveal region that usually manifests with
a slowly progressive decrease in visual acuity with
an onset in the ﬁfth to sixth decades of life.1–3
The prevalence of the disease has been estimated to
be as high as 0.1% among subjects aged 40 years and
older.4 Despite recent advances in the understanding
of the pathogenesis of this disease such as the identi-
ﬁcation of genetic loci associated with MacTel,5 many
aspects of the disease still remain unknown. Histopath-
ological studies have established that Müller cell
degeneration6 in the central retina occurs in the same
pattern as macular pigment depletion. This suggests
that neuroglial loss, resulting in impairment cone and
rod photoreceptor function, plays a central role in the
pathogenic mechanism of the disease.7,8 Clinically,
early manifestations of the disease include blunting
of the foveolar reﬂex, loss of retinal transparency,
crystalline deposits in the superﬁcial retinal layers,
and the presence of intraretinal cavities at the fovea.
Retinal alterations and abnormal macular pigment lev-
els initially manifest temporal to the fovea, whereas at
later stages, an oval area centered approximately 6°
horizontally and 5° vertically on the fovea is
1
affected.3,9 At advanced stages, lack of macular pig-
ment,10 formation of pigmented plaques along with
vascular remodeling, ﬁbrosis, and eventually subreti-
nal neovascularization2 may occur and may limit the
prognosis of central vision. To date, no effective treat-
ment to modify the course of disease in nonprolifer-
ative MacTel Type 2 is available.
Multiple imaging modalities have been established
as important parameters for assessing disease pro-
gression in MacTel, including ﬂuorescein angiogra-
phy, color fundus imaging, fundus autoﬂuorescence
(FAF) intensity imaging, optical coherence tomogra-
phy (OCT), and confocal blue reﬂectance imaging.11–
13
Fluorescence lifetime imaging ophthalmoscopy
(FLIO) is an imaging technology supplementing the
current armamentarium of multimodal retinal imag-
ing.14–17 Because the diagnosis of MacTel can be chal-
lenging especially at early stages of disease, FLIO may
serve as an additional tool for early detection of Mac-
Tel and possibly obtain information on disease pro-
gression. Because FLIO has been shown to detect
changes in macular pigment with high contrast18–20
changes in macular pigment speciﬁc lifetimes provide
information about macular photoreceptor or possibly
Müller cell loss. In a recent study, MacTel-speciﬁc
ﬂuorescence lifetime patterns have been reported.20
The purpose of this study was to conﬁrm these ﬁnd-
ings, to quantify disease-speciﬁc lifetime patterns in
patients with MacTel, and to provide longitudinal ﬂuo-
rescence lifetime data.
Methods
This prospective, cross-sectional study was con-
ducted at the University Hospital in Bern, Switzerland,
with the approval of the local ethics committee. The
study was performed in accordance with International
Conference on Harmonisation-Good Clinical Practice
(ICH-GCP) guidelines, which correspond to the
Health Insurance Portability and Accountability Act
of 1996 (HIPAA) regulations, which is in accordance
with the Declaration of Helsinki. This study is
registered at ClinicalTrials.gov (NCT01981148). All
patients and healthy controls were recruited at the
Ophthalmology outpatient department of the Univer-
sity Hospital, Bern, Switzerland. An informed consent
was signed before study entry.
Eyes of participants with a conﬁrmed diagnosis of
either nonproliferative or proliferative MacTel Type 2
were included in this study. Eyes with other retinal
pathologies affecting the macula, such as choroidal
neovascularization secondary to age-related macular
degeneration, diabetic retinopathy, and retinal vein
occlusion were excluded from the study.
All patients and healthy subjects underwent a com-
prehensive ophthalmologic examination with a mea-
surement of the best-corrected visual acuity (BCVA;
Early Treatment Diabetic Retinopathy Study [ETDRS]
letters and fundus examination). Before imaging,
maximal pupil dilation was achieved using tropica-
mide 0.5% and phenylephrine HCl 2.5%. Of both
eyes, color fundus images (Zeiss FF 450plus; Zeiss,
Oberkochen, Germany), ﬂuorescein angiography, FAF
images, and OCT scans of the macula (Heidelberg
Spectralis HRA + OCT; Heidelberg Engineering, Hei-
delberg, Germany), macular pigment optical density
(MPOD) measurements using a modiﬁed confocal
scanning laser ophthalmoscope (mpHRA; Heidelberg
Engineering), and ﬂuorescence lifetime images (FLIO)
were obtained. The Gass and Blodi classiﬁcation was
used categorize patients into phenotypic subgroups.
Brieﬂy, Stage 1 presents with occult vascular changes,
Stage 2 with no clinically visible telangiectasia, Stage
3 with prominent and dilated retinal venules, Stage 4
with retinal pigment clumping, and Stage 5 with sub-
retinal neovascularization.9
Fluorescence Lifetime Imaging Ophthalmoscope
A ﬂuorescence lifetime imaging ophthalmoscope
based on existing Heidelberg Engineering Spectralis
technology was used to acquire retinal ﬂuorescence
lifetime images from a 30° retinal ﬁeld. The principles
and safety details of FLIO have been described
previously.18
In summary, the technology is based on the
excitation of retinal FAF using a pulsed diode laser
(473 nm, 80 MHz). Two highly sensitive hybrid
photon-counting detectors (HPM-100-40; Becker &
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Hickl, Berlin, Germany) were used for detecting and
measuring ﬂuorescence photons in two separate wave-
length spectrums: a short spectral channel (SSC: 498–
560 nm) and a long spectral channel (LSC: 560–720
nm). Time-correlated single-photon counting modules
(SPC-150; Becker & Hickl) were used. In both wave-
length channels, at least 1,000 photons per pixel were
obtained to ensure reliable image quality. A high-
contrast confocal infrared image eye movement track-
ing system ensured that the correct location of each
photon was detected. The chi-square value evaluated
the exponential ﬁt.
The mean ﬂuorescence lifetime Ƭm was calculated
using the short and long lifetime components (Ƭ1 and
Ƭ2, respectively) with their relative amplitudes a1 and
a2.
Fluorescence Lifetime Data Analysis
The FLIO reader software (ARTORG Center for
Biomedical Engineering Research, University of Bern,
Switzerland) was used for analyses of all mean
ﬂuorescence lifetime data. For each eye, an FAF
intensity image with its correlating pseudocolor ﬂuo-
rescence lifetime image was performed. For quantiﬁ-
cation of retinal autoﬂuorescence lifetimes, a standard
ETDRS grid was used with a circle diameter of 1 mm
for the central area/fovea, 3 mm for the inner ring, and
6 mm for the outer ring.
Statistical Analysis
The mean ﬂuorescence lifetime data were analyzed
for both spectral channels. Data were presented as
mean ± SEM. To compare results and test for signif-
icant differences between groups, a Mann–Whitney
nonparametric test was used. Statistical analysis was
performed using GraphPad (Prism 6; GraphPad Soft-
ware Inc, La Jolla, CA).
Results
Fourteen consecutive patients (28 eyes) with a clinical
diagnosis of MacTel Type 2 (mean age: 67.8 ± 6.4
years, 64.3% male) and 28 eyes of 14 healthy subjects
(mean age 69.8 ± 6.4 years) were included in this study
(60% male). All participants were white and had no
concomitant ophthalmic diseases. One eye was pseudo-
phakic. The mean visual acuity was 67 ± 3 ETDRS
letters. Concerning systemic diseases, in patients with
MacTel Type 2, the prevalence of arterial hypertension
was 53.3%, hypercholesterolemia 50%, and diabetes
mellitus 35.7%. Four patients (28.6%) reported to be
ex-smokers. Follow-up examinations were performed
in four (28.6%) MacTel patients. Further details about
the investigated groups can be found in Table 1.
Autoﬂuorescence Lifetimes in Patients With MacTel
Type 2
The characteristic epicenter of the disease, located
temporal to the fovea, colocalized with distinct auto-
ﬂuorescence lifetimes in FLIO. In the temporal
parafoveolar area, we identiﬁed prolonged mean
retinal autoﬂuorescence lifetimes in a wedge-shaped
pattern of long ﬂuorescence lifetimes at early stages of
MacTel, whereas at advanced stages, an oval ring-
shaped lesion around the fovea was observed. Gener-
ally, the ﬂuorescence lifetime contrast of disease-
speciﬁc changes was best seen in the SSC (Figure 1).
When comparing autoﬂuorescence lifetime differ-
ences between patients with MacTel Type 2 and
healthy participants, there was a general prolongation
of mean ﬂuorescence lifetimes.
In particular, within the MacTel area (inferotempo-
ral region), signiﬁcant differences were found (P ,
0.0001) compared with the corresponding area in the
healthy control eyes (Figure 2).
In the MacTel cohort, mean lifetime values Ƭm
within the inner ring of the ETDRS grid were 488 ±
47 ps in the SSC and 410 ± 13 ps in the LSC. Thereby,
Ƭm was lengthened by 55% in the SSC and by 31% in
the LSC compared with healthy control eyes (P ,
0.001 and P , 0.01, respectively).
In MacTel eyes, mean lifetimes of T1 (SSC 543 ±
61 ps) were prolonged compared with T2 (301 ± 7 ps)
in healthy controls, suggesting that additional factors
to macular pigment loss such as degeneration of
Table 1. Patient Characteristics
Patient ID Sex Age (Years)
ETDRS
MacTel
Stage
FURight Left Right Left
MacTel 1 M 73 83 79 1 4
MacTel 2 M 69 29 69 5 5
MacTel 3 M 67 38 33 5 5
MacTel 4 M 67 51 73 4 5
MacTel 5 F 73 69 75 2 1 FU
MacTel 6 M 71 85 55 4 3
MacTel 7 M 54 82 40 2 5
MacTel 8 F 70 73 82 3 1
MacTel 9 M 66 78 83 1 1
MacTel 10 F 68 73 85 3 1 FU
MacTel 11 F 63 58 68 5 4
MacTel 12 F 62 73 45 2 2
MacTel 13 M 82 76 69 2 3 FU
MacTel 14 M 64 79 78 1 2 FU
BCVA, best-corrected visual acuity (ETDRS letters); F, female;
FU, follow-up available; M, male.
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photoreceptors or lipofuscin accumulation lead to lon-
ger mean lifetimes in T1 of MacTel patients.
The longest autoﬂuorescence lifetimes were identi-
ﬁed in eyes affected by MacTel within the temporal
quadrant (T1), followed by the inferior (I1), superior
(S1), and the nasal quadrants (N1) (Figure 2). Com-
pared with the healthy control population, the ﬂuores-
cence lifetimes were signiﬁcantly prolonged in the
temporal quadrant in both spectral channels (SSC
543 ± 61 ps vs. 304 ± 9 ps, P , 0.0001; LSC: 447
± 26 ps vs. 348 ± 11 ps, P , 0.0001).
Within the MacTel population, there was a signiﬁ-
cant difference (P = 0.0093) in retinal ﬂuorescence
lifetime between the temporal paracentral region com-
pared with the nasal sector. By contrast, a reversed
pattern was identiﬁed in healthy subjects, with the
temporal sector displaying shorter lifetimes in compar-
ison with the nasal sector (SSC: 304 ± 10 ps, LSC: 348
± 11 ps vs. SSC: 322 ± 11 ps, LSC: 348 ± 11 ps).
Fluorescence Lifetimes at Different Severity Grades
We analyzed differences in autoﬂuorescence life-
times between healthy participants and patients with
MacTel at ﬁve different severity grades according to
the Gass and Blodi classiﬁcation.1,9 Disease severity
was graded Stage 1 in 25% (7) eyes, Stage 2 in 21%
(6) eyes, Stage 3 in 14% (4) eyes, Stage 4 in 14% (4)
eyes, and Stage 5 in 25% (7) eyes.
The ETDRS subﬁelds were correlated with disease
severity (Table 2). Analysis of data in early-stage Mac-
Tel (Stage 1) revealed that in SSC, the mean ﬂuores-
cence lifetimes was signiﬁcantly prolonged in ETDRS
sectors T1 (P = 0.04), C (P , 0.0001) and I1 (P =
0.0046), in comparison to the healthy control group,
whereas differences in sectors N1 (P = 0.42) or T2 (P
= 0.3) were not signiﬁcant. In the LSC, we found no
signiﬁcant change in any ETDRS sectors between
healthy controls and Stage 1 MacTel patients.
The mean ﬂuorescence lifetime in the SSC measured
in areas of T1 were compared with N1 values. In healthy
controls, the mean autoﬂuorescence lifetime of the T1
sector was 3.2% shorter when compared with the N1
sector. However, in eyes with MacTel, T1 was prolonged
in Stage 1 by 6.9%, in Stage 2 by 5.4%, in Stage 3 by
11.5%, in Stage 4 by 15.7%, and in Stage 5 by 21.3%
when compared with mean lifetimes in N1, respectively.
Fluorescence Lifetime Imaging Ophthalmoscopy
and Multimodal Imaging Features
All patients displayed characteristic disease features
of MacTel Type 2 in FAF, OCT, and fundus
photography.
In OCT, MacTel-speciﬁc ﬁndings as described
below presented in various combinations but were
most prominent temporal to the fovea.
Fig. 1. Fundus autoﬂuorescence lifetime (color) and intensity (gray) images from the SSC (498–560 nm) and the LSC (560–720 nm) in a healthy
subject and a patient with MacTel showing prolongation (blue) of mean ﬂuorescence lifetime temporal to the fovea, with a reduction of short lifetimes
(red) within the fovea.
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The most common OCT ﬁnding in this study was
parafoveal hyporeﬂective spaces. These spaces corre-
sponded to areas of prolonged lifetimes located within
the perifoveal oval- or wedge-shaped region on
topographic FLIO maps. In addition, rarefaction of
the ellipsoid zone was a frequent ﬁnding. Areas with
ellipsoid zone loss generally featured longer Ƭm (Fig-
ure 3). Four eyes had evidence of crystalline deposits
on fundus photography and clinical examination.
Crystals were identiﬁed on fundus images and were
colocalized within the nerve ﬁber layer on OCT. The
areas with crystalline deposits were then investigated
with FLIO. Crystalline deposits featured distinctively
prolonged mean lifetimes, which were most apparent
in the short-wavelength channel, but still discernible in
the long-wavelength channel (Figure 3).
In advanced stages of MacTel (Stages 4), sharply
demarcated, parafoveal hypoﬂuorescent lesions
seen on FAF, corresponding to hyperpigmented
areas on fundus photography, were observed and
correlated with areas of prolonged autoﬂuorescence
lifetimes in FLIO. Neovascular membranes (Stage
5) seen as a thickening of the hyperreﬂective layer
on OCT also corresponded with circular lesions,
which led to pronounced prolongation of ﬂuores-
cence lifetimes.
The mean retinal thickness of the central subﬁeld
was 266 ± 14 mm and showed a correlation with the
BCVA, whereby increased retinal thickness was asso-
ciated with poorer ETDRS letter scores (r2 = 0.301, P
= 0.0025). Mean ﬂuorescence lifetimes of the central
subﬁeld of the SSC also showed correlation with
BCVA, whereby increased lifetimes were associated
with a poorer ETDRS letter score (r2 = 0.39, P =
0.0004; Figure 4).
Autoﬂuorescence and Macular Pigment
In healthy subjects, the shortest ﬂuorescence life-
times were seen within the macula, visualized as a red
color-coded signal on FLIO, probably originating from
macular pigment. When we compared mean ﬂuores-
cence lifetimes from the central subﬁeld of the ETDRS
grid of all MacTel patients with those of healthy age-
matched controls, Ƭm was prolonged by 107% in the
SSC (P = 0.0001) and by 30% in the LSC (P =
0.0016). However, patients with MacTel Stage 1 had
less changes in Ƭm of 48% in the SSC (P = 0.0417)
and 30% in the LSC (P = 0.1356).
Macular pigment optical density measurements
were obtained of 21 eyes with MacTel Type 2. In
general, patients displayed an abnormal distribution
with a reduced central MPOD signal and a surrounding
ring of increased density at about 6° eccentricity.
In general, in this study, MacTel patients exhibited
a reduced central macular pigment signal in compar-
ison with healthy controls as measured by a confocal
scanning laser ophthalmoscope (mpHRA). Although
in some patients a central peak in MPOD measure-
ments could still be found, the short ﬂuorescence
lifetime signal appeared irregularly shaped and smaller
in comparison with healthy eyes. At more advanced
stages, recordings displayed short ﬂuorescence life-
times in a ring-like dispersion pattern surrounding the
parafoveal area. Prolonged lifetime patterns correlated
with decreased macular pigment density on MPOD
measurements (Figure 5).
Analysis of Individual Fluorescence
Lifetime Components
We investigated the inﬂuence of individual lifetime
components (Ƭ1 and Ƭ2) and their corresponding am-
plitudes (a1 and a2) to observe changes seen in Ƭm.
Hyperpigmented plaques seen on fundus photogra-
phy could be isolated from the surrounding retina, due
to higher Ƭ1 and Ƭ2 components in comparison with
Fig. 2. A. Control eye from healthy subject and MacTel eye with
indicated way of data analysis. A standard ETDRS grid (center
[diameter; d = 1 mm], inner [d = 3 mm], and the outer [d = 6 mm]
ETDRS ring) was used for data averaging. FLIO SSC = 498 mm to 560
nm, ﬂuorescence lifetime images of the SSC. B. Quantitative analysis of
mean retinal autoﬂuorescence lifetime values in the SSC in healthy
subjects and MacTel patients. Box plots of mean ﬂuorescence lifetimes
(Ƭm) with 10 to 90 percentile of the following areas of the ETDRS grid:
central ( ), nasal sector (N1, ), temporal sector (T1, ), temporal outer
sector (T2, ), inferior sector (I1, ).
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the surrounding retina. Our data revealed that short
ﬂuorescence lifetimes (color coded red) could be iso-
lated at different stages of the disease. At early stages,
short lifetimes were found in the foveal center. As the
disease progressed, short lifetimes were less evident in
the macular region but appeared in a ring-like structure
surrounding the fovea. Shorter lifetimes had a higher
Ƭ1 component than the surrounding retina.
The MacTel area can be visualized using phasor
plots (see Figure 1, Supplemental Digital Content
1, http://links.lww.com/IAE/A944).21 The phasor
plot demonstrates the association between the short
and the long decay components, where short varia-
bles are located to the right side of the semicircle and
long components toward the left side. The mean au-
toﬂuorescence lifetime values measured are dispersed
on a virtual line between the short and the long
components. In the phasor plot, we observed a life-
time cloud correlating with the foveal area in healthy
subjects, which was absent in patients with MacTel
Type 2.
Follow-up Examinations
To assess disease-associated changes over time,
follow-up examinations were performed in 28.6% of
the eyes (n = 8). The average follow-up interval was
25 months, with a range from 6 months to 36 months.
There was an average of 2.6 letter decrease in BCVA,
which was statistically not signiﬁcant.
On follow-up, we observed a progression of pro-
longed ﬂuorescence lifetimes, radiating from the
center outward in an oval or round pattern (Figure
6A). Quantitative analysis of sector T1 showed a sig-
niﬁcant increase of Ƭm (22%) between initial and
follow-up measurements (baseline SSC: 337 ± 13 ps
vs. follow-up SSC: 411 ± 29 ps; r2 = 0.2480, P =
0.0409; Figure 6B).
Table 2. Fundus Autoﬂuorescence Lifetimes in MacTel
Patients and Healthy Subjects
C N1 S1 T1 T2 I1
Healthy controls (n = 14) 230 322 303 312 306 299
Grade 1 (n = 7) 316 339 353 363 325 340
Grade 2 (n = 6) 367 373 399 395 352 374
Grade 3 (n = 4) 391 394 421 447 389 414
Grade 4 (n = 4) 457 423 475 489 424 431
Grade 5 (n = 7) 613 566 603 745 619 639
All MacTel 461 454 468 542 460 477
Mean ﬂuorescence lifetime from the SSC (498–560) in different
regions of interest of the ETDRS grid, including the central foveal
area (C), nasal sector (N1), inner temporal sector (T1), outer tem-
poral sector (T2), and inferior sector (I1) in healthy controls, pa-
tients with MacTel Stages 1 to 5, and all MacTel patients (n =
number of subjects).
Fig. 3. Multimodal imaging of
a patient with MacTel Type 2 in
a nonproliferative stage. Fundus
photography (color fundus
[CF]) showing parafoveal loss
of retinal transparency and reti-
nal crystals; fundus auto-
ﬂuorescence image (FAF)
showing mild increase of foveal
autoﬂuorescence; ﬂuorescence
angiogram (FA) with late-phase
leakage; spectral domain OCT
horizontal scans 1 to 3, with
indicated green line.
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Discussion
Fluorescence lifetime imaging ophthalmoscopy is
a relatively new imaging modality allowing to detect
subtle changes within the retina and therefore provides
additional information over other retinal imaging
techniques.14,15,18,19,22 Advancements in retinal imag-
ing over the past decade have increased our under-
standing of pathological features in MacTel.
However, as clinical changes can be subtle, particu-
larly in early stages of disease, imaging techniques to
identify changes earlier and to monitor longitudinal
changes noninvasively are important.
In our study of 28 eyes of patients with MacTel Type
2, unique features of mean retinal ﬂuorescence lifetimes
were identiﬁed, which are in keeping with a recently
published report.20 We observed signiﬁcantly pro-
longed lifetimes within the affected MacTel area, with
the inferotemporal region showing the most pro-
nounced changes with a general prolongation even in
the very early stages of this disease. In addition, MPOD
measurements correlated well with FLIO measure-
ments, with both methods showing a loss of macular
pigment with progression of the disease. The macular
pigment typically encompasses the fovea, where a cen-
tral well-circumcised round region of shortened life-
times has been described as a normal ﬁnding in
topographic FLIO maps.18,19 Despite the large variation
of macular pigment concentration in the normal popu-
lation, the pattern of distribution in MPOD measure-
ments as well as in FLIO measurements is relatively
uniform. A peak concentration is generally found at the
Fig. 4. A. Correlation of BCVA
(ETDRS letters) with central
retinal thickness (r2 = 0.301, P =
0.0025). B. Correlation of
BCVA (ETDRS letters) with
mean ﬂuorescence lifetimes of
the SSC (r2 = 0.39, P = 0.0004).
Fig. 5. Comparison of MPOD proﬁles obtained using 2-wavelength FAF in two patients with MacTel Type 2 showing reduced central macular pigment
with corresponding FAF lifetime images in the SSC (FLIO, SSC = 498–560 nm) (A) at MacTel Stage 2 residual macular pigment (MP) at the fovea, and
(B) at MacTel Stage 5 with a surrounding ring of preserved MPOD at about 6° eccentricity.
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foveal center with an eccentric decrease and fading at
8° and more. In patients with MacTel Type 2, we
observed at later stages of the disease that the macular
pigment lifetime signature was completely absent, and
a marked oval-shaped irregular area of shortened life-
times in a region of up to 4° to 7° surrounding the
foveolar was identiﬁed. This was further illustrated
using the phasor plot analysis demonstrating the central
depletion of macular pigment (see Figure 1, Supple-
mental Digital Content 1, http://links.lww.com/IAE/
A944). These ﬁndings are consistent with previous ob-
servations where retinal abnormalities have been sug-
gested to present temporally to the fovea initially on
fundus examination,23 imaging,24 and functional
assessment using microperimetry.25 However, histo-
pathological and clinicopathological studies of this dis-
tinct MacTel region conﬁrmed ﬁndings of depleted
macular pigment and Müller cell dysfunction.6,7
Fig. 6. A. Disease progression
within 24 months FLIO (SSC),
fundus AF, and MPOD (base-
line, left). Follow-up examina-
tion (right) shows clear disease
progression with prolongation
of temporal lifetimes and
a reduction in the macular pig-
ment density. B. Mean ﬂuores-
cence lifetime of the short
spectral of the temporal sector
(T1) from the ETDRS grid.
Mean and SD of Tm at baseline
(left) and follow-up. C. Bar-
graph showing progression of
mean ﬂuorescence lifetimes
from the SSC from baseline to
follow-up visit (r2 = 0.2480, P =
0.0409).
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In contrast to FAF, in which lipofuscin is the
predominant ﬂuorophore in terms of ﬂuorescence
intensity in the retina, the FLIO technique has the
ability to detect and characterize ﬂuorescence lifetime
data from other ﬂuorophores, and their interaction with
each other as well as the embedding matrix.26 How-
ever, there is still some controversy around the origin
of the measured signal, and further clariﬁcation on the
involved ﬂuorophores is needed. To date, besides lip-
ofuscin, collagen melanin, elastin, FAF, and NAD(P)
H have been suggested to contribute to the ﬂuores-
cence lifetime signal.18
An important ﬁnding of this study was a prolonged
foveal and perifoveal lifetime pattern identiﬁed in
MacTel eyes, which exceeded the prolongation that
would be expected by macular pigment alone. There-
fore, other factors seem to play a role in the observed
ﬂuorescence lifetime changes. Clinical characteristics
such as intraretinal crystalline deposit accumulation,
where we observed prolonged lifetimes outside areas of
the macular pigment region, as well as hyperplastic
retinal pigment epithelium migration and abnormalities
in the juxtafoveolar retinal vessels may additionally
contribute to the identiﬁed prolonged lifetimes. We have
previously shown that ellipsoid zone loss with a pre-
served retinal pigment epithelium results in Ƭm prolon-
gation.15,18 This association was also found in patients
with MacTel (Figure 3). As intact photoreceptors have
been shown to contribute to short lifetime signals, pos-
sibly due to generation of components of the visual
cycle such as all-trans retinal, loss of photoreceptors will
lead to longer lifetimes in MacTel patients.
Changes seen on FLIO at different disease stages
seem disease speciﬁc for MacTel Type 2 and, as such,
our study is supportive of the clinical applicability of
this device in the diagnosis and monitoring of MacTel.
In our study, longer lifetimes were signiﬁcantly associ-
ated with more advanced clinical disease stages.
Although in the early stages of MacTel we found subtle
wedge-shaped prolongation of ﬂuorescence lifetimes
changes starting temporal to the fovea, with progressing
disease, these changes involved the foveal center.
Furthermore, ﬂuorescence lifetime patterns change over
time with enlargement of areas of long Ƭm. Therefore,
retinal autoﬂuorescence lifetimes can be used to monitor
disease progression and may serve as an objective read-
out to assess future therapeutic interventions.
This study has several limitations, including the
patient number and heterogeneity between patients. This
cohort included a larger number of patients with MacTel
Type 2 in advanced stages with evidence of neo-
vascularization. Because MacTel Type 2 is a relatively
rare condition, more deﬁnite conclusions could be
drawn with larger samples through multicenter studies.
Conclusion
The characteristic lifetime changes in patients with
MacTel Type 2, particularly in the inferotemporal
region and the nasal–temporal difference, may be used
as an additional marker for the clinical diagnosis and
progression of the disease. The topographic FLIO
maps offer a novel diagnostic tool in the investigation
of eyes with MacTel and may provide information
about macular pigment and possibly photoreceptor
loss. Additional longitudinal data will be needed to
determine the value of FLIO as a noninvasive
screening, diagnostic imaging modality, and as
a measure of disease progression in MacTel Type 2.
Key words: ﬂuorescence lifetimes, fundus auto-
ﬂuorescence, ophthalmic imaging, MacTel, macular
telangiectasia type 2, macula.
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